Email this article Use of endogenous cholesterol and its metabolite as markers of cyp450 metabolic activity
- Authors: Smirnov V.V.1,2, Krasnykh L.M.1, Vasilenko G.F.1, Ramenskaya G.V.1,2, Checha O.A.1
-
Affiliations:
- Scientific Centre for Expert Evaluation of Medicinal Products
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 26, No 2 (2020)
- Pages: 93-97
- Section: Clinical pharmacology and pharmaceuticals
- URL: https://medjrf.com/0869-2106/article/view/42547
- DOI: https://doi.org/10.18821/0869-2106-2020-26-2-93-97
- ID: 42547
Cite item
Open Access
Access granted
Abstract
This article analyzes the application of the method for determining the activity of CYP3A4 by determining the concentration of endogenous cholesterol and its metabolite/4β-hydroxycholine in blood plasma. It also provides information on the convergence assessment of data obtained using alternative methods for determining the activity of the same CYP450 isoenzyme (CYP3A4) using different substrates: cholesterol and cortisol.
Keywords
Full Text
About the authors
V. V. Smirnov
Scientific Centre for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: vall@mail.mipt.ru
ORCID iD: 0000-0002-8232-6682
MD, PhD
Russian Federation, MoscowL. M. Krasnykh
Scientific Centre for Expert Evaluation of Medicinal Products
Email: krasnyh@expmed.ru
ORCID iD: 0000-0003-3650-6014
MD, PhD
Russian Federation, MoscowG. F. Vasilenko
Scientific Centre for Expert Evaluation of Medicinal Products
Email: vaselek1945@list.ru
ORCID iD: 0000-0001-7940-1664
MD, PhD
Russian Federation, MoscowG. V. Ramenskaya
Scientific Centre for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: ramenskaia@mail.ru
ORCID iD: 0000-0001-8779-3573
MD, PhD, DSc, Professor
Russian Federation, MoscowO. A. Checha
Scientific Centre for Expert Evaluation of Medicinal Products
Email: olga.tchecha@yandex.ru
ORCID iD: 0000-0002-7900-1078
MD, PhD
Russian Federation, MoscowReferences
- Liu Y.T., Hao H.P., Liu C.X., Wang G.J., Xie H.G. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev. 2007; 39(4): 699-721. doi: 10.1080/03602530701690374.
- Thelen K., Dressman J.B. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009; 61(5): 541-58. doi: 10.1211/jpp/61.05.0002.
- Wojnowski L., Kamdem L.K. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol. 2006; 2(2): 171-82. doi: 10.1517/17425255.2.2.171.
- Hohmann N., Haefeli W.E., Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 2016; 12(5): 479-97. doi: 10.1517/17425255.2016.1163337.
- Fuhr U., Jetter A., Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther. 2007; 81(2): 270-83. doi: 10.1038/sj.clpt.6100050.
- Galteau M.M., Shamsa F. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. 2003; 59(10): 713-33. doi: 10.1007/s00228-003-0690-3.
- Mao J., Martin I., McLeod J., Nolan G., van Horn R., Vourvahis M. et al. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. Drug Metab Rev. 2017; 49(1): 18-34. doi: 10.1080/03602532.2016.1239630.
- Bodin K., Bretillon L., Aden Y., Bertilsson L., Broomé U., Einarsson C. et al. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans. Evidence for involvement of cytochrome P450 3A4. J Biol Chem. 2001; 276(42): 38685-9. doi: 10.1074/jbc.M105127200.
- Gebeyehu E., Engidawork E., Bijnsdorp A., Aminy A., Diczfalusy U., Aklillu E. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J. 2011; 11(2): 130-7. doi: 10.1038/tpj.2010.16.
- Hole K., Gjestad C., Heitmann K M., Haslemo T., Molden E., Bremer S. Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. Eur. J. Clin. Pharmacol. 2017; 73(3): 317-24. doi: 10.1007/s00228-016-2178-y.
- Lee J., Kim A.H.J., Yi S.J., Lee S.H., Yoon S.H., Yu K.S. et al. Distribution of exogenous and endogenous CYP3A markers and related factors in healthy males and females. AAPS J. 2017; 19(4): 1196-204. doi: 10.1208/s12248-017-0090-8.
- Diczfalusy U., Kanebratt K.P., Bredberg E., Andersson T.B., Böttiger Y., Bertilsson L. 4β-Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol. 2009; 67(1): 38-43. doi: 10.1111/j.1365-2125.2008.03309.x.
- Björkhem-Bergman L., Bäckströn T., Nylén H., Rönquist-Nii Y., Bredberg E., Andersson T.B. et al. Comparison of endogenous 4b-hydroxycholesterol with midazolam as markers for cyp3a4 induction by rifampicin. Drug Metab. Dispos. 2013; 41(8): 1488-93. doi: 10.1124/dmd.113.052316.
- Jetter A., Kinzig-Schippers M., Skott A., Lazar A., Tomalik-Scharte D., Kirchheiner J. et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur. J. Clin. Pharmacol. 2004; 60(3): 165-71. doi: 10.1007/s00228-004-0754-z.
- Tomalik-Scharte D., Lütjohann D., Doroshyenko O., Frank D., Jetter A., Fuhr U. Plasma 4Β-hydroxycholesterol: an endogenous CYP3A metric. Clin. Pharmacol. Ther. 2009; 86(2): 147-53. doi: 10.1038/clpt.2009.72.
Supplementary files
